Progenity Establishes Inflammatory Bowel Disease Clinical Advisory Board
June 17, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the formation of its Inflammatory Bowel Disease Clinical Advisory...
Progenity Announces $40 Million Private Placement
June 10, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, June 10, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced that it has entered into a definitive securities...
Progenity Launches Strategic Transformation into Biotech Company, Eliminating Costs of Progenity Genetics Lab and Focusing on Robust, Innovative R&D Pipeline
June 02, 2021 07:00 ET
|
Progenity, Inc.
Closure of genetics lab and other operational improvements expected to result in approximately 70% reduction of annual capital required for operations – from more than $180 million currently to...
Progenity Provides Results from Key Study for Its Targeted Therapeutics Program
May 26, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced results from a further study for the company’s Targeted Therapeutics...
Progenity Announces Poster Presentations at Digestive Disease Week 2021
May 24, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, May 24, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the presentation of two posters related to the company’s Targeted...
Progenity Provides Corporate Update and Reports First Quarter 2021 Financial Results
May 13, 2021 16:03 ET
|
Progenity, Inc.
Reports revenues of $24.5 million in the first quarter of 2021, up 72% from prior quarter Announced pre-validation data for its Preecludia™ test showed strong performance consistent with...
Progenity Provides Preliminary Results from Key Studies for its Targeted Therapeutics Program
May 12, 2021 07:29 ET
|
Progenity, Inc.
SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced preliminary results, subject to final audited study reports by its...
Global Stoma/Ostomy Care Market 2020: Market is Projected to Reach US$3.8 Billion by the year 2027, Trailing a Post COVID-19 CAGR of 4.2%
December 07, 2020 05:18 ET
|
Research and Markets
Dublin, Dec. 07, 2020 (GLOBE NEWSWIRE) -- The "Stoma/Ostomy Care - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Focus on Stoma Quality of...
Pandion Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
November 16, 2020 16:01 ET
|
Pandion Therapeutics, Inc.
- Enrollment and dosing complete in Phase 1a clinical trial of PT101; top-line results expected early 2021- PT627 systemic PD-1 agonist development candidate nominated; IND-enabling studies expected...
Innovation Pharmaceuticals Plans for Phase 2 Trial of New Treatment for Ulcerative Colitis
March 05, 2020 08:00 ET
|
Innovation Pharmaceuticals Inc.
Active ulcerative colitis targeted; multiple ascending dose design (low, mid, high doses and placebo)Endpoints: clinical remission (Mayo scoring); endoscopic remission; biomarkers, and others ...